Title
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcomaIfosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Research group
Faculteit Geneeskunde
Publication type
article
Publication
Berlin,
Subject
Pharmacology. Therapy
Human medicine
Source (journal)
Cancer chemotherapy and pharmacology. - Berlin
Source (book)
SATELLITE SYMP ON IFOSFAMIDE IN THE TREATMENT OF SARCOMAS, AT THE 6TH EUROPEAN CONF ON CLINICAL ONCOLOGY AND CANCER NURSING, OCT 27, 1991, FLORENCE, ITALY
Volume/pages
31(1993):s:[2], p. S204-S209
ISSN
0344-5704
ISI
A1993KW66100009
Carrier
E
Target language
English (eng)
Affiliation
University of Antwerp
Abstract
The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft-tissue sarcoma. Treatment consisted of an intravenous bolus injection of doxorubicin at a dose of 50 mg/m2 followed by a 24-h infusion of ifosfamide at 5 g/m2 plus mesna, with therapy being repeated every 3 weeks until disease progression or unacceptable toxicity occurred. Of the 203 patients entered, 175 were evaluable for response. The overall response rate was 35% (95% confidence interval, 28%-42%), with 9% of patients achieving complete responses and 26% showing partial responses. The median time to progression was 29 weeks for all evaluable patients and 67, 40, and 28 weeks for complete and partial responders and patients with stable disease, respectively. The median duration of survival was 58 weeks. Myelosuppression was the dose-limiting toxicity, resulting in leukopenia (World Health Organization grades 3 and 4) in 73% of the evaluable patients. Other side effects were rare and usually well manageable.
E-info
https://repository.uantwerpen.be/docman/iruaauth/35c584/bb74890.pdf
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1993KW66100009&DestLinkType=RelatedRecords&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1993KW66100009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1993KW66100009&DestLinkType=CitingArticles&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
Handle